Cargando…

PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay

BACKGROUND: Programmed death ligand 1 (PD-L1) has shown potential as a therapeutic target in numerous solid tumors. Its prognostic significance has also been established in pancreatic ductal adenocarcinoma (PDAC). The present study aimed to explore PD-L1 expression in PDAC cases in a large Chinese c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Xiaolong, Sun, Jian, Wu, Huanwen, Luo, Yufeng, Wang, Lili, Lu, Junliang, Zhang, Zhiwen, Guo, Junchao, Liang, Zhiyong, Liu, Tonghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389094/ https://www.ncbi.nlm.nih.gov/pubmed/29378617 http://dx.doi.org/10.1186/s13000-017-0678-4

Ejemplares similares

Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma
por: Wang, Lili, et al.
Publicado: (2017)

Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma
por: Wang, Li, et al.
Publicado: (2016)

Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition
por: Zhang, Zhiwen, et al.
Publicado: (2019)

Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes
por: Lu, Junliang, et al.
Publicado: (2020)

Multi‐omics analysis of intra‐tumoural and inter‐tumoural heterogeneity in pancreatic ductal adenocarcinoma
por: Liu, Xiaoqian, et al.
Publicado: (2022)

Coexpression of EGFR and CXCR4 Predicts Poor Prognosis in Resected Pancreatic Ductal Adenocarcinoma
por: Wu, Huanwen, et al.
Publicado: (2015)

Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy
por: Li, Ruiyu, et al.
Publicado: (2021)

AREG mediates the epithelial-mesenchymal transition in pancreatic cancer cells via the EGFR/ERK/NF-κB signalling pathway
por: Wang, Li, et al.
Publicado: (2020)

Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA
por: Wu, Huanwen, et al.
Publicado: (2022)

Restored CD8(+)PD-1(+) T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma
por: Zhu, Qian, et al.
Publicado: (2022)

SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-κB axis
por: Ma, Qiang, et al.
Publicado: (2017)

PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation
por: Ma, Qiang, et al.
Publicado: (2017)

Retraction: PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation
por: Ma, Qiang, et al.
Publicado: (2018)

Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review
por: Wang, Yizhi, et al.
Publicado: (2020)

Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines
por: Huanwen, Wu, et al.
Publicado: (2009)

Oral mycobiota and pancreatic ductal adenocarcinoma
por: Wei, Ailin, et al.
Publicado: (2022)

Transducin-Like Enhancer of Split-1 Inhibits Malignant Behaviors in vitro and Predicts a Better Prognosis in Pancreatic Ductal Adenocarcinoma
por: Wang, Yizhi, et al.
Publicado: (2020)

A novel cuproptosis-related gene model predicts outcomes and treatment responses in pancreatic adenocarcinoma
por: Liu, Qixian, et al.
Publicado: (2023)

Multiplex Patient-Based Drug Response Assay in Pancreatic Ductal Adenocarcinoma
por: Armstrong, Andrew, et al.
Publicado: (2021)

Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma
por: Vaz, Arokia Priyanka, et al.
Publicado: (2015)

PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
por: Azad, Abul, et al.
Publicado: (2016)

RNA m(6)A Demethylase ALKBH5 Protects Against Pancreatic Ductal Adenocarcinoma via Targeting Regulators of Iron Metabolism
por: Huang, Rui, et al.
Publicado: (2021)

Circular RNA expression in pancreatic ductal adenocarcinoma
por: Zhang, Qian, et al.
Publicado: (2019)

Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective
por: Zhang, Wu-Hu, et al.
Publicado: (2020)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma
por: Liu, Jing, et al.
Publicado: (2019)

TRPM2 promotes the proliferation and invasion of pancreatic ductal adenocarcinoma
por: Lin, Rui, et al.
Publicado: (2018)

Evaluation of the diagnostic ability of laminin gene family for pancreatic ductal adenocarcinoma
por: Yang, Chengkun, et al.
Publicado: (2019)

Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment
por: Elrakaybi, Asmaa, et al.
Publicado: (2022)

The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC)
por: Wheatley, Roseanna C., et al.
Publicado: (2022)

Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis
por: Pezzilli, Raffaele, et al.
Publicado: (2011)

Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells
por: Zhang, Hui, et al.
Publicado: (2014)

A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma
por: Zhang, Yiyin, et al.
Publicado: (2019)

Fecal elastase, an assay for exocrine pancreatic insufficiency, has clinical utility in patients with pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2020)

Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma
por: Gao, He-Li, et al.
Publicado: (2020)

Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club
por: Winter, Katarzyna, et al.
Publicado: (2019)

Apoptotic pathways in pancreatic ductal adenocarcinoma
por: Hamacher, Rainer, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_alhjhhkjqkkn8atldj66fp3co7